Key Insights
- The projected fair value for Coloplast is kr.1,455 based on 2 Stage Free Cash Flow to Equity
- Coloplast's kr.901 share price signals that it might be 38% undervalued
- Analyst price target for COLO B is kr.913 which is 37% below our fair value estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Coloplast A/S (CPH:COLO B) as an investment opportunity by taking the forecast future cash flows of the company and discounting them back to today's value. This will be done using the Discounted Cash Flow (DCF) model. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
View our latest analysis for Coloplast
Is Coloplast Fairly Valued?
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (DKK, Millions) | kr.6.10b | kr.6.86b | kr.8.45b | kr.10.5b | kr.11.9b | kr.13.0b | kr.13.9b | kr.14.7b | kr.15.2b | kr.15.7b |
Growth Rate Estimate Source | Analyst x7 | Analyst x7 | Analyst x2 | Analyst x1 | Est @ 13.24% | Est @ 9.58% | Est @ 7.01% | Est @ 5.21% | Est @ 3.96% | Est @ 3.07% |
Present Value (DKK, Millions) Discounted @ 5.0% | kr.5.8k | kr.6.2k | kr.7.3k | kr.8.6k | kr.9.3k | kr.9.7k | kr.9.9k | kr.9.9k | kr.9.8k | kr.9.6k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = kr.86b
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.0%. We discount the terminal cash flows to today's value at a cost of equity of 5.0%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = kr.16b× (1 + 1.0%) ÷ (5.0%– 1.0%) = kr.394b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= kr.394b÷ ( 1 + 5.0%)10= kr.241b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is kr.327b. In the final step we divide the equity value by the number of shares outstanding. Compared to the current share price of kr.901, the company appears quite undervalued at a 38% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Coloplast as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.0%, which is based on a levered beta of 0.976. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Coloplast
- Debt is well covered by earnings.
- Earnings growth over the past year underperformed the Medical Equipment industry.
- Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.
- Shareholders have been diluted in the past year.
- Annual earnings are forecast to grow for the next 3 years.
- Trading below our estimate of fair value by more than 20%.
- Debt is not well covered by operating cash flow.
- Dividends are not covered by earnings and cashflows.
- Annual earnings are forecast to grow slower than the Danish market.
Next Steps:
Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. What is the reason for the share price sitting below the intrinsic value? For Coloplast, we've put together three essential aspects you should assess:
- Risks: Be aware that Coloplast is showing 3 warning signs in our investment analysis , and 2 of those are concerning...
- Future Earnings: How does COLO B's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the CPSE every day. If you want to find the calculation for other stocks just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CPSE:COLO B
Coloplast
Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.
Fair value second-rate dividend payer.